View as “PDF version”
More and more medication infusions are being done in the home, due to both convenience and economic reasons. Often these are for chemotherapy drugs. But there have been problems with home infusion of other drugs as well. Our August 2016 What's New in the Patient Safety World column “Home Infusion Therapy Pitfalls” highlighted a case related to home infusion of vancomycin. And, increasingly, we are seeing home infusion of biologic drugs used for treating immune-mediated disorders.
Baker et al. (Baker 2021) recently analyzed data on over 750,000 biologic infusions in over 57,000 patients, 4.5% of which were administered at home vs. 95.5% administered in facilities. They found that home infusions were associated with 25% increased odds of ED or hospital admission on the same or next day after the infusion (odds ratio 1.25) and 28% increased odds of discontinuation of the biologic after the ED or hospital admission (OR, 1.28). There was no difference in mortality rates between the two sites.
68% of patients were female, likely reflecting the increased incidence of immune-mediated disorders in women, and mean age of patients receiving infusions was 50.1 years. However, those receiving biologic infusions at home were younger, more likely to be male, and had lower Charlson Comorbidity scores than those receiving infusions in facilities.
The top 3 biologics administered at home were infliximab (60.6%), natalizumab (19.6%), and vedolizumab (7.9%), and the top 3 biologics administered at a facility were infliximab (52.1%), abatacept (15.4%), and natalizumab (13.3%).
Note that 25.5% of home infusion patients actually received their first infusion at a facility, followed by subsequent infusions of the same biologic at home.
Baker et al. hypothesize that administration of biologics at home involves less intensive monitoring, less physician oversight, and lack of immediate access to urgent medical treatment in the event of an acute infusion reaction and that this can result in delayed care and a more frequent need for escalation of care.
Although permanent discontinuation of a biologic after ED or hospital admission was a rare outcome, it occurred more also frequently after home infusions compared with facility infusions.
In the editorial accompanying the Baker study, Calip et al. (Calip 2021) point out numerous methodological problems and biases inherent in the Baker study. They caution that one cannot conclude causal attribution in such a study. But they acknowledge the evidence provided in the Baker study is highly relevant to understanding the risks and benefits of these disease-altering biologic therapies in different treatment settings.
It is probably no accident that the American College of Rheumatology recently released a position statement on patient safety and site of service for biologics (ACR 2021). It contains the following 3 position statements pertinent to infusion of biologics:
Other
considerations pointed out by the ACR are that home infusions do not allow for
rigorous maintenance of conditions such as recommended temperature, storage
away from sunlight, and proper reconstitution or dosing.
It further cautions that financial considerations related to potential cost savings of home infusions should not override patient safety and standards of care. The position of the ACR is that “proper administration of biologics should take place under the close supervision of a physician in a provider’s office, infusion center or hospital rather than in a patient’s home, unless the patient and provider decide that home infusion is in the patient’s best interest.“ It also suggests that forcing patients to receive infusions at home or in facilities not supervised by a trained provider may reduce access to these critical therapies.
The
ACR opposes policies that require home infusion of biologics. “In the absence
of an
agreement between the provider and the patient that home infusion is the best
option due to extenuating circumstances (i.e., lack of transportation or
medical comorbidities) and that the risks of home infusion are outweighed by
the benefits, required home infusion is an unnecessary risk to patients and
violates current clinical standards of practice.”
Some of our prior columns on patient safety issues in the home:
References:
Baker MC, Weng Y, Fairchild R, Ahuja N, Rohatgi N. Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017. JAMA Netw Open 2021; 4(6): e2110268
Calip GS, Yerram P, Ascha MS. Nonrandomized Comparison of Adverse Events Following Facility- and Home-Infused Biologics Using Real-World Data. JAMA Netw Open 2021; 4(6): e2111156
ACR (American College of Rheumatology). Position Statement. Patient Safety and Site of Service for Biologics. American College of Rheumatology 2021; June 2021
https://www.rheumatology.org/Portals/0/Files/Biologics-Patient-Safety-and-site-of-Service.pdf
Print
“PDF
version”
http://www.patientsafetysolutions.com/